Loading…
Hosted by Unknown Host · 🇺🇸 US · EN-US · 65 episodes
Established thought leaders with verified media credentials.
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts
Unknown Host hosts Community Health Media, a health show with 65 episodes published.
A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pe
Can we improve outcomes by changing treatment before radiographic progression occurs?In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-pos
HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it
The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly.Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care
The treatment landscape for perioperative gastric cancer is changing rapidly.In this expert roundtable, leading GI oncology specialists discuss the practice-changing impact of the MATTERHORN trial, the role of immunother
Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma?In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce,
How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer?In this full-length discussion, Dr. Ursa Brown-Glaberman and Dr. Karthik Giridhar explore one
How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer?Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-chan
Can T-DXd plus pertuzumab finally replace the CLEOPATRA regimen as the new first-line standard for metastatic HER2-positive breast cancer?In this comprehensive discussion from ASCO 2026, Dr. Jason Mouabbi, Dr. Fengting Y
How is T-DXd reshaping treatment for patients with early-stage HER2-positive breast cancer?Dr. Abi Siva and Dr. Carey Anders discuss the evolving role of T-DXd across the treatment continuum, including the latest data fr
Metastatic triple-negative breast cancer has long been one of the most challenging breast cancer subtypes to treat. But with the emergence of ADCs, the treatment landscape is rapidly evolving.In this in-depth discussion
How should clinicians integrate T-DXd across the entire HER2-positive breast cancer treatment continuum?Dr. Megan Kruse, Dr. William Gradishar, and Dr. Ajaz Khan discuss the evolving role of trastuzumab deruxtecan (T-DXd
How should clinicians approach endocrine resistance in ER-positive metastatic breast cancer?Dr. Mark Pegram and Dr. Seth Wander explore the evolving science of endocrine resistance, ESR1 mutations, liquid biopsy testing,
TNBC has long been one of the most difficult breast cancer subtypes to treat. But with ADCs reshaping the treatment landscape, are we finally entering a new era for metastatic TNBC?In this in-depth discussion, Dr. Jason
How will DESTINY-Breast11 and DESTINY-Breast05 change the treatment of early-stage HER2-positive breast cancer?Dr. Gregory Vidal, Dr. Pooja Advani, and Dr. Tari King discuss the landmark approvals of trastuzumab deruxtec
Three new approvals for trastuzumab deruxtecan (T-DXd) are reshaping the treatment landscape for HER2-positive breast cancer.Dr. Hope Rugo, Dr. Sarah Hurvitz, and Dr. Jennifer Tseng discuss the clinical impact of DESTINY
What is the optimal treatment strategy after progression on a CDK4/6 inhibitor in HR-positive, HER2-negative metastatic breast cancer?Dr. Nusayba Bagegni and Dr. Philip Lammers discuss how they approach treatment sequenc
What should replace chemotherapy in the first-line treatment of immunotherapy-ineligible metastatic triple-negative breast cancer(TNBC)?Dr. Sangeetha Reddy and Dr. Ahmed Elkhanany discuss the evolving role of antibody-dr
The treatment for early-stage HER2-positive breast cancer has entered a new era.Dr. Mabel Mardones and Dr. Joyce O'Shaughnessy discuss how they are implementing trastuzumab deruxtecan (T-DXd) following the landmark DESTI
The treatment landscape for early-stage HER2-positive breast cancer is evolving rapidly.In this discussion, Dr. Joyce O'Shaughnessy, Dr. Anthony Lucci, and Dr. Mothaffar Rimawi explore how DESTINY-Breast11 (DB11) and DES
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Community Health Media has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their health audience.
Community Health Media is hosted by Unknown Host. The show is categorised under health (fitness) and has published 65 episodes.
Community Health Media has published 65 episodes.
Community Health Media regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.
Community Health Media is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Community Health Media hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Community Health Media average 44 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Community Health Media's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 12 days ago.